It was reported that low XBP1 spliced/unspliced ratio (XBP1s/XBP1u) is significantly correlated with improved overall survival and better clinical outcome in MM patients treated with immunomodulatory agent thalidomide [24]. Here, XBP1 is linked to Miyoshi myopathy.